EGFR and non-small cell lung carcinoma: However, despite the identification of common mutations, there are still no additional pathological factors that can be used to predict treatment response and improvement in survival.<h4>Methods</h4>This retrospective study utilized data from a multi-center registry of NSCLC patients with EGFR mutations who were treated with first-line osimertinib therapy between March 2017 and December 2024.